Inhibition of MELK produces potential anti‐tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway

We aimed to investigate the biological function of MELK and the therapeutic potential of OTSSP167 in human bladder cancer (BCa). First, we observed overexpression of MELK in BCa cell lines and tissues and found that it was associated with higher tumour stage and tumour grade, which was consistent with transcriptome analysis. High expression of MELK was significantly correlated with poor prognosis in BCa patients, and MELK was found to have a role in the cell cycle, the G1/S transition in mitosis, and DNA repair and replication. Furthermore, BCa cells presented significantly decreased proliferation capacity following silencing of MELK or treatment with OTSSP167 in vitro and in vivo. Functionally, reduction in MELK or treatment of cells with OTSSP167 could induce cell cycle arrest and could suppress migration. In addition, these treatments could activate phosphorylation of ATM and CHK2, which would be accompanied by down‐regulated MDMX, cyclin D1, CDK2 and E2F1; however, p53 and p21 would be activated. Opposite results were observed when MELK expression was induced. Overall, MELK was found to be a novel oncogene in BCa that induces cell cycle arrest via the ATM/CHK2/p53 pathway. OTSSP167 displays potent anti‐tumour activities, which may provide a new molecule‐based strategy for BCa treatment.

[1]  T. Lawrence,et al.  Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. , 2019, Cancer research.

[2]  Yanhua Tian,et al.  Structural basis of allosteric regulation of Tel1/ATM kinase , 2019, Cell Research.

[3]  Hyun-A Seong,et al.  Thr55 phosphorylation of p21 by MPK38/MELK ameliorates defects in glucose, lipid, and energy metabolism in diet-induced obese mice , 2019, Cell Death & Disease.

[4]  Haitao Zhao,et al.  Alterations in DNA Damage Repair Genes in Primary Liver Cancer , 2019, Clinical Cancer Research.

[5]  Jian Gao,et al.  Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis , 2019, OncoTargets and therapy.

[6]  E. Amini,et al.  Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016 , 2019, The Journal of urology.

[7]  Yusuke Nakamura,et al.  Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma , 2019, Molecular Cancer Therapeutics.

[8]  E. V. Van Allen,et al.  Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites , 2018, Clinical Cancer Research.

[9]  Yujiao Lu,et al.  Sodium Fluoride Arrests Renal G2/M Phase Cell-Cycle Progression by Activating ATM-Chk2-P53/Cdc25C Signaling Pathway in Mice , 2018, Cellular Physiology and Biochemistry.

[10]  Youguo Chen,et al.  Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer , 2018, Cancer medicine.

[11]  Tingting Duan,et al.  Nuclear lamina dysfunction triggers a germline stem cell checkpoint , 2018, Nature Communications.

[12]  J. Twisk,et al.  MELK Inhibition in Diffuse Intrinsic Pontine Glioma , 2018, Clinical Cancer Research.

[13]  Kenneth L. Jones,et al.  Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma , 2018, Endocrinology.

[14]  Ya Zhang,et al.  Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia , 2018, Oncogene.

[15]  Xue Zhu,et al.  Corosolic acid induces cell cycle arrest and cell apoptosis in human retinoblastoma Y-79 cells via disruption of MELK-FoxM1 signaling. , 2018, Oncology reports.

[16]  W. Gu,et al.  Peli1 Modulates the Subcellular Localization and Activity of Mdmx. , 2018, Cancer research.

[17]  Liang Zhao,et al.  Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK , 2018, BMC Cancer.

[18]  F. Baron,et al.  Maternal embryonic leucine zipper kinase inhibitor OTSSP 167 has preclinical activity on multiple myeloma bone disease by , 2018 .

[19]  A. Lin,et al.  MELK expression correlates with tumor mitotic activity but is not required for cancer growth , 2018, eLife.

[20]  M. Dunning,et al.  Identification of potential therapeutic targets in prostate cancer through a cross‐species approach , 2018, EMBO molecular medicine.

[21]  B. Xiang,et al.  Corrigendum to “Preservation of Myocardial Perfusion and Function by Keeping Hypertrophied Heart Empty and Beating for Valve Surgery: An In Vivo MR Study of Pig Hearts” , 2017, BioMed research international.

[22]  Michael R. Green,et al.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway. , 2017, Cell reports.

[23]  H. Ludwig,et al.  Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma , 2017, Haematologica.

[24]  Chengjie Sun,et al.  In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell: Erratum , 2018, Theranostics.

[25]  Sipei Wu,et al.  XRRA1 Targets ATM/CHK1/2-Mediated DNA Repair in Colorectal Cancer , 2017, BioMed research international.

[26]  T. Noda,et al.  Phosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis , 2017, PLoS pathogens.

[27]  J. Gagneur,et al.  Caenorhabditis elegans CES-1 Snail Represses pig-1 MELK Expression To Control Asymmetric Cell Division , 2017, Genetics.

[28]  Yusuke Nakamura,et al.  p53-independent p21 induction by MELK inhibition , 2017, Oncotarget.

[29]  A. Schoetzau,et al.  MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. , 2017, Gynecologic oncology.

[30]  N. Seki,et al.  The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes , 2017, Journal of Human Genetics.

[31]  M. Bollen,et al.  Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. , 2013, The Journal of Biological Chemistry.

[32]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[33]  K. Hui,et al.  MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. , 2016, Cancer letters.

[34]  N. Gray,et al.  Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival , 2016, Proceedings of the National Academy of Sciences.

[35]  A. Jakubowiak,et al.  Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells , 2016, Blood Cancer Journal.

[36]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[37]  H. Bartelink,et al.  Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer , 2016, Clinical Cancer Research.

[38]  Yusuke Nakamura,et al.  Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells , 2016, Oncotarget.

[39]  Yusuke Nakamura,et al.  Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor , 2016, Oncotarget.

[40]  M. Bollen,et al.  MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells , 2015, Bioscience reports.

[41]  Y. Cheng,et al.  Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer , 2015, Breast Cancer Research and Treatment.

[42]  H. Niu,et al.  Bladder Tumor Heterogeneity: The Impact on Clinical Treatment , 2015, Urologia Internationalis.

[43]  W. Hiddemann,et al.  Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia , 2014, Oncotarget.

[44]  R. Schlegel,et al.  MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells , 2014, eLife.

[45]  Tao Du,et al.  Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway , 2014, Molecular Cancer.

[46]  Kaushal Joshi,et al.  Tumor‐Specific Activation of the C‐JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53‐Dependent Manner , 2013, Stem cells.

[47]  Kaushal Joshi,et al.  MELK-Dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells , 2013, Stem cells.

[48]  Yusuke Nakamura,et al.  Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer , 2012, Oncotarget.

[49]  H. Klocker,et al.  The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer , 2012, Journal of Molecular Medicine.

[50]  Y. le Page,et al.  A functional analysis of MELK in cell division reveals a transition in the mode of cytokinesis during Xenopus development , 2011, Journal of Cell Science.

[51]  C. Brennan,et al.  Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. , 2010, Cancer cell.

[52]  J. Ku,et al.  Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. , 2010, Carcinogenesis.

[53]  Carlos Caldas,et al.  Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer , 2009, Breast Cancer Research.

[54]  Jiandong Chen,et al.  Regulation of MDMX nuclear import and degradation by Chk2 and 14‐3‐3 , 2006, The EMBO journal.

[55]  William Arbuthnot Sir Lane,et al.  ATM and Chk2‐dependent phosphorylation of MDMX contribute to p53 activation after DNA damage , 2005, The EMBO journal.